Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICM-203 in Knee Osteoarthritis
NCT04875754Phase 2Completed
- Start
- Mar 2022
- Primary completion
- Feb 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ICM-203 in osteoarthritis (OA) (3 arms). Primary endpoints: Treatment-Emergent Adverse Events at 52 weeks and Severity of Treatment-Emergent Adverse Events at 52 weeks. Started Mar 2022; status: completed.
02
Drugs
ICM-203
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04875754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04875754.